Johnson & Johnson (JNJ) boosted its sales and profit outlook for the year after reporting second-quarter financial results that beat Wall Street expectations, aided by growth in its pharmaceuticals business.
The company raised its full-year sales guidance of $71.5 billion to $72.2 billion, up from the sweetened forecast of $71.2 billion to $71.9 billion the company issued in April. It also increased its adjusted 2016 earnings guidance to a range of $6.63 to $6.73 per share, up from $6.53 to $6.68.
13:16 Wells Fargo earnings: 96 cents per share, vs. expected EPS of $122
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High3
21:52 Netflix nears 94 million subscribers 10 years after streaming launch16
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft8